StockUnited StatesNasdaqGS

COAG

Hemab Therapeutics Holdings, Inc.

Healthcare · Biotechnology

44.50USD

-0.0700 (-0.16%)

Description Historical Financials Relative Value Research News Discussion OptionsPrice Chart ↗Fundamental Chart ↗

Fiscal Year End12/2025

Last Quarter End06/2026 Q2

Current/T12M(USD)

Issue Data

Last PxUSD / 44.50

P/E—

Dvd Ind Yld—

P/B4.58

P/S—

Curr EV/T12M EBITDA-18.7

Mkt Cap (USD)2.1B

Curr EV (USD)1.6B

Per Share Data

EPS T12M-53.87

DPS—

Bk Val Per Sh9.73

Rev/Sh—

Cash/Sh9.79

Curr Shares Out46.7M

FCF/Sh-2.42

Cash Flow Analysis

P/CF-28.7

Curr P/FCF-28.6

CF/NI1.0

Dvd P/O0.0%

Cash Gen/Cash Reqd—

Csh Dvd Cov—

CFO/Sales—

Eff Interest Rate—

Growth Potential

Dil EPS 1Y Gr—

Cap 1Y Gr-53.2%

BPS 1Y Gr—

R&D To Sales—

Retention Rate100.0%

Rev 1Y Gr—

FCF 1Y Gr—

Assets 1Y Gr—

Profitability

EBITDA-0.1B

EBIT-0.1B

Operating Margin0.0%

Pretax Margin—

Net Margin0.0%

ROA-15.9%

ROE-45.7%

ROC-18.1%

Asset Turnover—

Structure

Current Ratio35.85

Quick Ratio35.48

Debt/Assets0.2%

Debt/Com Eq0.2%

Net Debt/EBITDA2.88

Tot Debt/Capital0.2%

Gross Margin0.0%

EBIT/Int Exp—

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.

Reading financial statements from SEC filings…

A first visit to a security takes a few seconds.